2023
Standardized Clinical Pathways Improve Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department
Forward J, Thomas D, O'Malley S, Berkwitt A, Calhoun C, Krishnamurti L, Pashankar F. Standardized Clinical Pathways Improve Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department. Blood 2023, 142: 2315. DOI: 10.1182/blood-2023-181285.Peer-Reviewed Original ResearchVaso-occlusive episodesSickle cell diseasePediatric emergency departmentMinutes of arrivalPain managementEmergency departmentClinical pathwayIntranasal fentanylYears post implementationHydromorphone PCAPain medicationPediatric patientsJune 30 thPain medication administrationVaso-occlusive painPercent of patientsPercentage of patientsQuality improvement projectOutcome one yearElectronic medical recordsPost implementationHealth care systemFirst analgesicED visitsED encounters
2022
Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease
Gillard A, Gagnon R, Pashankar F, Balsamo L, Grafft N, Miranda J, Boruchov D, Neri C, Sprinz P, Longyear C. Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease. Clinical Child Psychology And Psychiatry 2022, 28: 1012-1023. PMID: 36503316, DOI: 10.1177/13591045221145425.Peer-Reviewed Original Research
2021
Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt
Youssry I, ElGhamrawy M, Seif H, Balsamo L, Pashankar F, Mahrous M, Salama N. Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt. International Journal Of Hematology 2021, 115: 399-405. PMID: 34792734, DOI: 10.1007/s12185-021-03260-1.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh lactate dehydrogenaseCell diseaseCognitive impairmentRisk factorsLactate dehydrogenaseCairo University Children's HospitalOlder ageSickle cell disease patientsUniversity Children's HospitalPossible risk factorsMagnetic resonance angiographyMagnetic resonance imagingHydroxyurea therapyTranscranial DopplerChildren's HospitalDisease patientsUnivariate analysisEarly initiationPatientsResonance angiographyImpaired cognitionResonance imagingIntelligence quotient (IQ) testDisease
2013
Weight Status of Children With Sickle Cell Disease
Chawla A, Sprinz PG, Welch J, Heeney M, Usmani N, Pashankar F, Kavanagh P. Weight Status of Children With Sickle Cell Disease. Pediatrics 2013, 131: e1168-e1173. PMID: 23460681, DOI: 10.1542/peds.2012-2225.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBaseline Hb levelsHb levelsBMI percentileWeight statusCell diseaseHigher baseline Hb levelsSCD-related complicationsRetrospective chart reviewObesity-related conditionsOverweight/obesityRecent clinic visitYears of ageCalendar year 2007Select comorbiditiesChart reviewClinic visitsDL increaseElevated BMIHemoglobin levelsObese statusSickle genotypeUnderweight individualsHb SSDemographic informationCandidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea
Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea. PLOS ONE 2013, 8: e55709. PMID: 23409025, PMCID: PMC3567082, DOI: 10.1371/journal.pone.0055709.Peer-Reviewed Original ResearchConceptsSickle cell diseaseFetal hemoglobin levelsHemoglobin levelsCell diseaseFetal hemoglobinBaseline levelsAdult sickle cell diseasePediatric sickle cell diseaseSubset of childrenPharmacologic therapyHydroxyurea therapyClinical severityPediatric diseasesInduced levelsSignificant associationTherapeutic inductionCandidate single nucleotide polymorphismsDiseaseSingle nucleotide polymorphismsHemoglobinSequence variantsChildrenTherapyBaselineHydroxyurea
2012
Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease
Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatric Blood & Cancer 2012, 60: 653-658. PMID: 23129068, PMCID: PMC3625668, DOI: 10.1002/pbc.24381.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHU useCell diseaseHematology providersBivariate analysisPediatric sickle cell diseaseBenefits of hydroxyureaMajor therapeutic effectMultivariate logistic regressionLong-term safetyPotential side effectsParental knowledgeBetter parental knowledgeHU usersHydroxyurea useInter-institutional variabilityParents of childrenChildren ages 5Label useSickle genotypeTherapeutic effectClinical careEffective treatmentSide effectsClinical practice
2011
Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease
Pashankar F, Manwani D, Lee M, Green N. Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease. Blood 2011, 118: 4841. DOI: 10.1182/blood.v118.21.4841.4841.Peer-Reviewed Original ResearchTricuspid regurgitant jet velocityElevated pulmonary artery pressurePulmonary artery pressureSickle cell diseaseArtery pressureCell diseaseEffect of hydroxyureaPulmonary hypertensionElevated tricuspid regurgitant jet velocityWhite blood cell countMean reticulocyte countTotal daily doseRegurgitant jet velocityRole of inflammationMean oxygen saturationBlood cell countFetal hemoglobinMean corpuscular volumeRepeat echocardiogramAverage followEndothelial dysfunctionDaily doseEndothelial functionPersistent elevationMean age
2010
Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease
Oyeku S, Green N, Pashankar F, Giardina P, Mullen C, Driscoll C. Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease. Blood 2010, 116: 255. DOI: 10.1182/blood.v116.21.255.255.Peer-Reviewed Original ResearchSickle cell diseaseYears of ageEfficacy of hydroxyureaHU useUse of hydroxyureaMajority of providersCell diseaseSickle cell genotypeProvider barriersClinical indicationsHematology providersNIH Consensus Development ConferencePediatric sickle cell diseaseLong-term side effectsNational evidence-based guidelinesProvider levelBroader clinical indicationsChronic pain useAcute chest syndromePhase III trialsPatients ages 1Dose of hydroxyureaEvidence-based guidelinesOff-label useConsensus Development Conference
2007
Sickle cell disease complicated by post‐streptococcal glomerulonephritis, cerebral hemorrhage and reversible posterior leucoencephalopathy syndrome
Pashankar FD, Ment LR, Pearson HA. Sickle cell disease complicated by post‐streptococcal glomerulonephritis, cerebral hemorrhage and reversible posterior leucoencephalopathy syndrome. Pediatric Blood & Cancer 2007, 50: 864-866. PMID: 17973321, DOI: 10.1002/pbc.21321.Peer-Reviewed Original ResearchConceptsReversible posterior leucoencephalopathy syndromeAcute post-streptococcal glomerulonephritisPost-streptococcal glomerulonephritisSickle cell diseaseCell diseaseHomozygous hemoglobin SS diseaseCentral nervous system eventsHemoglobin SS diseasePrimary cerebral infarctionNervous system eventsSickle cell nephropathyReversible causesCerebral infarctionCerebral hemorrhageIntracerebral hemorrhageSS diseaseHemorrhageDiseaseGlomerulonephritisPatientsPrognosisSyndromeHypertensionNephropathyComplications